Lisi Group (FII) Q3 2026 TU earnings summary

Executive summary

• Nine-month revenue reached €1,416.0M, up 8.0% reported and 10.3% like-for-like; aerospace growth outweighed automotive weakness.

• Q3 revenue rose 12.8% reported and 12.1% like-for-like, with aerospace growth accelerating to 22.5% reported.

Financial highlights

• Nine-month revenue was €1,416.0M versus €1,311.2M in 2025; Q3 revenue was €473.2M versus €419.5M.

• Nine-month revenue included a €24.8M negative currency impact, a +€4.7M scope effect from Hungary and a -€8.0M effect from Ankit's deconsolidation.

• 2025 comparatives exclude LISI MEDICAL revenue of €44.7M in Q1, €42.4M in Q2 and €44.9M in Q3, following its October 2025 sale.

Outlook and guidance

• 2026 objectives reaffirmed: significantly improve key financial indicators for a fourth consecutive year, led by recurring EBIT, and generate positive operating free cash flow.

• Aerospace Q4 priorities include expanding capacity and improving operating efficiency amid supply-chain strain.

• Automotive priorities include completing the Puiseux reorganization, integrating the Hungarian entity, consolidating Livonia operations into Monterrey and adjusting inventory.